Literature DB >> 12566597

Lack of association between Alzheimer's disease and Gln-Arg 192 Q/R polymorphism of the PON-1 gene in an Italian population.

Roberto Pola1, Eleonora Gaetani, Andrea Flex, Laura Gerardino, Francesco Aloi, Roberto Flore, Michele Serricchio, Paolo Pola, Roberto Bernabei.   

Abstract

Alzheimer's disease (AD) is characterized by deposition of oxidized low-density lipoprotein (LDL) forming the senile plaque and by structural changes and cell death in acetylcholine-producing neurons. Paraoxonase-1 (PON-1) is a secreted protein primarily associated with high-density lipoproteins (HDL) and participates in the prevention of LDL oxidation. PON-1 is also an arylesterase that hydrolyzes paraoxon, an active toxic metabolite of parathion, thus providing protection against organophosphate poisoning and metabolization of environmental neurotoxins that might be responsible for neurodegeneration with aging. Serum levels of PON-1 are genetically determined and strongly influenced by a common polymorphism on the position 192 of the PON-1 gene. The aim of this study was to evaluate whether the polymorphism of the PON-1 gene is associated with AD. We studied 124 Italian subjects affected by probable AD and 135 age- and sex-matched controls. The distribution of PON-1 genotypes was 64 QQ, 46 QR, 14 RR in the AD patients and 57 QQ, 59 QR, 19 RR in the control subjects. No statistically significant difference was found between the two groups in our population (p = 0.130 for homozygous QQ, p = 0.279 for heterozygous QR, and p = 0.502 for homozygous RR). These results suggest that the human Gln-Arg 192 Q/R polymorphism of the PON-1 gene is not associated with AD in an Italian population. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566597     DOI: 10.1159/000067975

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  7 in total

1.  Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease.

Authors:  Porat M Erlich; Kathryn L Lunetta; L Adrienne Cupples; Carmela R Abraham; Robert C Green; Clinton T Baldwin; Lindsay A Farrer
Journal:  Neurobiol Aging       Date:  2010-10-27       Impact factor: 4.673

2.  Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome.

Authors:  Dor Mohammad Kordi-Tamandani; Mohammad Hashemi; Nooshin Sharifi; Mahmoud Ali Kaykhaei; Adam Torkamanzehi
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

Review 3.  The Relationship between Cancer and Paraoxonase 1.

Authors:  Irma Martha Medina-Díaz; Néstor Ponce-Ruíz; Aurora Elizabeth Rojas-García; José Francisco Zambrano-Zargoza; Yael Y Bernal-Hernández; Cyndia Azucena González-Arias; Briscia S Barrón-Vivanco; José Francisco Herrera-Moreno
Journal:  Antioxidants (Basel)       Date:  2022-03-31

Review 4.  Pharmacogenetics of paraoxonases: a brief review.

Authors:  D I Draganov; B N La Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-25       Impact factor: 3.000

5.  Alzheimer's Disease and Paraoxonase 1 (PON1) Gene Polymorphisms.

Authors:  Mohsen Saeidi; Raheleh Shakeri; Abdoljalal Marjani; Safoura Khajeniazi
Journal:  Open Biochem J       Date:  2017-06-13

Review 6.  Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?

Authors:  Enrica Rossini; Federico Biscetti; Maria Margherita Rando; Elisabetta Nardella; Andrea Leonardo Cecchini; Maria Anna Nicolazzi; Marcello Covino; Antonio Gasbarrini; Massimo Massetti; Andrea Flex
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

7.  Profile of the Paraoxonase 1 (PON1) Gene 192Q/R Polymorphism and Clinical Associations among Older Singaporean Chinese with Alzheimer's and Mixed Dementia.

Authors:  Dennis C C Seow; Qi Gao; Philip Yap; Jia Min Gan; Hui Ling Chionh; Su Chi Lim; Lei Feng; Tze Pin Ng
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2016-02-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.